ZIMURA - Sponsored by Ophthotech, Corp.Active Study | Duration: 72 weeks
Zimura is a phase 2B, multicenter, randomized, masked, controlled trial to study the safety and efficacy of ZimuraTM administered as an intravitreal injection in patients with geographic atrophy secondary to dry age-related macular degeneration. Enrolled subjects will be randomized in a 1:2:2 ratio to the following dose groups: ZimuraTM 2mg/eye + Sham, ZimuraTM 4mg/eye (administered as two injections of ZimuraTM 2mg/eye) or Sham + Sham. The study plans to enroll approximately 277 patients. Trial participation is 18 months.